Ferumoxytol

Generic Name: Ferumoxytol

Brand Names: Feraheme

Drug Type: Small Molecule

Chemical Formula: Fe_₃O_₄

CAS Number: 722492-56-0

Unique Ingredient Identifier: G6N3J05W84

Background: Ferumoxytol is an intravenously administered iron preparation indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) .
...

Indication: This drug is indicated for the treatment of iron deficiency anemia in adult patients who have experienced intolerance to oral iron or have experienced an unsatisfactory response to oral iron or

who have chronic kidney disease (CKD) .

Associated Conditions: Iron Deficiency Anemia (IDA)

Associated Therapies: -

Clinical Trials

DEtection of Cellular Inflammation With FERumoxytol in the HEART

Phase 2

Completed

Conditions: Cardiac Transplant
Cardiac Sarcoid
Myocarditis
Healthy Volunteers

Interventions: Drug: Ferumoxytol

First Posted Date: 2014-12-18

Last Posted Date: 2017-05-03

Lead Sponsor: University of Edinburgh

Target Recruit Count: 58

Registration Number: NCT02319278

Locations: 🇬🇧
Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
🇬🇧
Golden Jubilee National Hospital, Glasgow, United Kingdom
🇬🇧
Royal Brompton Hospital, London, United Kingdom

Innovative MRI Techniques to Improve Treatment Stratification of Patients With Esophageal Cancer

Not Applicable

Completed

Conditions: Esophageal Neoplasms

Interventions: Drug: Ferumoxytol

First Posted Date: 2014-10-01

Last Posted Date: 2019-01-16

Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Target Recruit Count: 41

Registration Number: NCT02253602

Locations: 🇳🇱
Academic Medical Center, Amsterdam, Noord Holland, Netherlands

Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery

Phase 1

Terminated

Conditions: Anemia
Cardiovascular Disease

Interventions: Drug: EPO
Drug: Feraheme

First Posted Date: 2014-07-15

Last Posted Date: 2020-10-23

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 5

Registration Number: NCT02189889

Locations: 🇺🇸
Clements University Hospital, Dallas, Texas, United States

Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers

Phase 2

Completed

Conditions: Bladder Cancer
Kidney Cancer
Prostate Cancer

Interventions: Drug: Ferumoxytol
Diagnostic Test: Magnetic Resonance Imaging (MRI)

First Posted Date: 2014-05-19

Last Posted Date: 2019-09-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 43

Registration Number: NCT02141490

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

DCE MRI in Patients With Pancreatic Cancer

Not Applicable

Active, not recruiting

Conditions: Familial Pancreatic Cancer
Pancreatic Adenocarcinoma
Pancreatic Intraductal Papillary-Mucinous Neoplasm

Interventions: Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Drug: Ferumoxytol

First Posted Date: 2014-02-25

Last Posted Date: 2024-10-02

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 77

Registration Number: NCT02070705

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance

Not Applicable

Completed

Conditions: Renal Transplant Rejection

Interventions: Drug: Feraheme
Other: MRI-GE Healthcare 3 Tesla magnet

First Posted Date: 2013-12-09

Last Posted Date: 2018-05-11

Lead Sponsor: Stanford University

Target Recruit Count: 21

Registration Number: NCT02006108

Locations: 🇺🇸
Lucile Packard Children's Hospital, Stanford, California, United States

Diagnostic Accuracy of Ferumoxytol-Enhanced MRI for Detecting Lymph Node Metastases in Colorectal Cancer

Not Applicable

Withdrawn

Conditions: Colorectal Cancer

Interventions: Drug: Ferumoxytol
Other: Magnetic Resonance Imaging

First Posted Date: 2013-11-14

Last Posted Date: 2016-05-20

Lead Sponsor: Scott Potenta, MD, PhD

Registration Number: NCT01983371

Locations: 🇺🇸
University of Vermont Medical Center, Burlington, Vermont, United States

High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases

Withdrawn

Conditions: Multiple Sclerosis

Interventions: Drug: Feraheme
Drug: Gadolinium-based contrast

First Posted Date: 2013-10-31

Last Posted Date: 2018-09-10

Lead Sponsor: Stanford University

Registration Number: NCT01973517

Locations: 🇺🇸
Richard M. Lucas Center for Imaging (of Stanford University), Stanford, California, United States
🇺🇸
Stanford Hospitals and Clinics, Stanford, California, United States

Ferumoxytol for Iron-Deficiency Anemia in Chronic Kidney Disease and Peritoneal Dialysis Patients

Phase 4

Completed

Conditions: Iron-Deficiency Anemia
Inflammation
Oxidative Stress

Interventions: Drug: Ferumoxytol

First Posted Date: 2013-09-16

Last Posted Date: 2015-04-13

Lead Sponsor: Georges Ouellet

Target Recruit Count: 15

Registration Number: NCT01942460

Locations: 🇨🇦
Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada

Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study

Not Applicable

Completed

Conditions: Papillary Carcinoma of Thyroid Gland
Metastatic Medullary Thyroid Cancer
Follicular Thyroid Cancer Lymph Node Metastasis

Interventions: Drug: Ferumoxytol
Device: Nanoparticle MRI

First Posted Date: 2013-08-23

Last Posted Date: 2017-06-06

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 12

Registration Number: NCT01927887

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy